Advertisement
The number of health data breaches has steadily increased since 2010

Number of Health-Related Data Breaches Increasing

0
Health plans had most records breached from 2010 to 2017, but providers breached most often
Preventable cardiovascular events place a considerable health and economic burden on the United States

Preventable Cardiovascular Events Are Big Economic Burden

0
About 16.3 million events, totaling $173.7 billion in hospitalization costs, could occur in 2017 to 2021

September 2018 Briefing – Pulmonology

0
Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for September 2018. This roundup includes the latest...
Laparoscopic antireflux surgery is safe and well-tolerated in patients with idiopathic pulmonary fibrosis and abnormal acid gastroesophageal reflux

Anti-Reflux Surgery Promising in Idiopathic Pulmonary Fibrosis

0
In phase 2 study, surgery for abnormal acid GER in IPF patients was safe, well-tolerated
Patients with chronic obstructive pulmonary disease who have comorbidities are more likely to experience readmission or mortality and less likely to receive beneficial treatments

Readmission, Death Risk Higher in COPD With Comorbidities

0
Patients with COPD and comorbidities have reduced odds of receiving beneficial treatments
The risk of recurrence after incident venous thromboembolism is high

Risk of Venous Thromboembolism Recurrence High

0
At 6 months, rates for provoked, unprovoked, cancer-related VTE are 6.8, 6.92, 9.06 per 100 person-years
From 2016 to 2017

More Non-Elderly Americans Uninsured in 2017 Versus 2016

0
More than 700,000 Americans uninsured in 2017 versus 2016, despite broad economic improvement
Arikayce (amikacin liposome inhalation suspension) has been approved by the U.S. Food and Drug Administration to treat lung disease caused by Mycobacterium avium complex bacteria among patients who do not respond to conventional therapies

FDA Approves New Drug for Antibiotic-Resistant Lung Disease

0
Arikayce approved to treat lung disease caused by Mycobacterium avium complex bacteria
Nintedanib plus sildenafil does not provide benefit over nintedanib alone for patients with idiopathic pulmonary fibrosis and diffusion capacity of the lungs for carbon monoxide of 35 percent or less of the predicted value

Nintedanib Plus Sildenafil No Better Than Nintedanib in IPF

0
No benefit with sildenafil in idiopathic pulmonary fibrosis with severe impairment in gas exchange
More than half of physicians experience burnout

Physicians Often Don’t Address Their Burnout

0
Same traits that help doctors excel at their jobs make them more likely to experience burnout